Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007677 · ClinicalTrials.gov registry record · Phase 2
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
A Phase 2 study of Hereditary Angioedema, sponsored by Astria Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT06007677 is a Phase 2 study of Hereditary Angioedema that is active but no longer recruiting, run by Astria Therapeutics. The registered enrollment target is 56 participants, below the 72-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06007677, a Phase 2 study of Hereditary Angioedema, is active but no longer recruiting, sponsored by Astria Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Conditions Studied
Interventions
- DRUG STAR-0215
Study Locations (20)
Other
- Diagnostic Consultative Center Convex Ltd. - Sofia
- Institute of Clinical Immunology/Allergology, Faculty Hospital, Hradec Kralove - Hradec Králové
- Charité Universitätsmedizin Berlin - Berlin
- Johann Wolfgang Goethe-Universität Frankfurt - Frankfurt
- Universitätsklinikum Ulm - Ulm
- Szpital Uniwersytecki w Krakowie - Krakow
California
- UC San Diego US HAEA Angioedema Center - San Diego
- Raffi Tachdjian MD, Inc - Santa Monica
- Allergy & Asthma Clinical Research - Walnut Creek
Alabama
- Allervie Clinical Research - Birmingham
Arizona
- Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD - Scottsdale
Arkansas
- Acuro Research - Little Rock
Maryland
- Institute for Asthma and Allergy, PC - Chevy Chase
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2031-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06007677
The ClinicalTrials.gov registry entry for NCT06007677 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (22% lower). The listed sponsor is Astria Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which STAR-0215 is the first listed.
NCT06007677 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06007677 about?
NCT06007677 is a clinical study titled "A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema". The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
What is the current status of trial NCT06007677?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2023-09-26. Estimated completion is 2031-03.
What conditions does trial NCT06007677 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT06007677?
The interventions under investigation include: STAR-0215 (DRUG).
Who is sponsoring clinical trial NCT06007677?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007677 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
COMPLETED · Phase 2
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
RECRUITING · Phase 4
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.